Literature DB >> 9370113

Pioglitazone reduces smooth muscle cell density of rat carotid arterial intima induced by balloon catheterization.

M Igarashi1, Y Takeda, N Ishibashi, K Takahashi, S Mori, M Tominaga, Y Saito.   

Abstract

The effect of pioglitazone on balloon catheterization-induced carotid arterial intimal thickening lesion of male Wistar fatty rats and its littermates (Wistar lean rats) was investigated. Pioglitazone was administered via gastric tube at 10 mg/kg/day to 12-week-old rats for 7 days. Age-matched rats without pioglitazone were used as respective controls. Each rat was catheterized using a balloon catheter inserted from the left femoral artery to the left common carotid artery, and the endothelium in the left common carotid artery was denuded. Rats were then treated with pioglitazone for 14 days post catheterization and the left common carotid artery was removed and stained with Elastica-Masson and anti-alpha-smooth muscle actin antibody. In addition, for smooth muscle cell (SMC) culture, pioglitazone was administered at 10 mg/kg/day for 28 days to a separate group of 12-week-old rats, and the aortic medial outgrowth rate of their SMCs was measured. Age-matched rats without pioglitazone were prepared as respective controls. In comparison with the area ratio of the thickened intima/media of fatty rats without treatment, those of fatty rats with treatment and lean rats without treatment were significantly decreased by approximately 60%, and also that of lean rats with treatment to 27%. With anti-alpha-smooth muscle actin antibody staining, almost all cells present in intimal thickening were positive. Treatment with pioglitazone reduced the amount of anti-alpha-smooth muscle actin antibody-staining cells. In addition, the outgrowth rate of SMCs at day 10 compared to that in fatty rats without treatment decreased to 42% in fatty rats with treatment, 29% in lean rats without treatment and 23% in lean rats with treatment, respectively. Therefore, pioglitazone has an inhibitory effect on the growth of SMCs, and consequently suppressed carotid intimal thickening. Furthermore, this inhibitory effect was enhanced in diabetes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9370113     DOI: 10.1055/s-2007-979074

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  10 in total

Review 1.  Peroxisome proliferator activated receptor gamma: a potential therapeutic target in the management of ischaemic heart disease.

Authors:  J S Sidhu; J C Kaski
Journal:  Heart       Date:  2001-09       Impact factor: 5.994

2.  Nifedipine suppresses neointimal thickening by its inhibitory effect on vascular smooth muscle cell growth via a MEK-ERK pathway coupling with Pyk2.

Authors:  A Hirata; M Igarashi; H Yamaguchi; A Suwabe; M Daimon; T Kato; M Tominaga
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

Review 3.  Pioglitazone.

Authors:  P S Gillies; C J Dunn
Journal:  Drugs       Date:  2000-08       Impact factor: 9.546

4.  p38 mitogen-activated protein kinase (MAPK) promotes cholesterol ester accumulation in macrophages through inhibition of macroautophagy.

Authors:  Shuang Mei; Haihua Gu; Adam Ward; Xuefeng Yang; Huailan Guo; Ka He; Zhenqi Liu; Wenhong Cao
Journal:  J Biol Chem       Date:  2012-02-21       Impact factor: 5.157

Review 5.  Metabolic and additional vascular effects of thiazolidinediones.

Authors:  Fabrice M A C Martens; Frank L J Visseren; Jacinthe Lemay; Eelco J P de Koning; Ton J Rabelink
Journal:  Drugs       Date:  2002       Impact factor: 9.546

6.  Efficacy and safety of low-dose pioglitazone after primary coronary angioplasty with the use of bare metal stent in patients with acute myocardial infarction and with type 2 diabetes mellitus or impaired glucose tolerance.

Authors:  Jin Yokoyama; Naoyuki Sutoh; Takumi Higuma; Daisuke Horiuchi; Chisato Katoh; Takashi Yokota; Takashi Echizen; Shingo Sasaki; Hiroyuki Hanada; Tomohiro Osanai; Ken Okumura
Journal:  Heart Vessels       Date:  2007-05-21       Impact factor: 2.037

Review 7.  PPARgamma and its ligands: therapeutic implications in cardiovascular disease.

Authors:  Luis Villacorta; Francisco J Schopfer; Jifeng Zhang; Bruce A Freeman; Y Eugene Chen
Journal:  Clin Sci (Lond)       Date:  2009-02       Impact factor: 6.124

8.  Transcriptional Control of Vascular Smooth Muscle Cell Proliferation by Peroxisome Proliferator-Activated Receptor-gamma: Therapeutic Implications for Cardiovascular Diseases.

Authors:  Florence Gizard; Dennis Bruemmer
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

9.  Use of rosiglitazone before and after vascular injury in hypercholesterolemic rabbits: Assessment of neointimal formation.

Authors:  Alexandre Alessi; Olímpio Ribeiro França Neto; Paulo Roberto Slud Brofman; Camila Prim; Lucia Noronha; Ruy Fernando Kuenzer Caetano Silva; Liz Andréa Villela Baroncini; Dalton Bertolim Précoma
Journal:  Thromb J       Date:  2008-08-27

10.  Retrospective review of superficial femoral artery stenting in diabetic patients: thiazolidinedione use may decrease reinterventions.

Authors:  Karen L Walker; Daniel B Walsh; Philip P Goodney; Samantha A Connell; David H Stone; Richard J Powell; Eva M Rzucidlo
Journal:  BMC Cardiovasc Disord       Date:  2014-12-11       Impact factor: 2.298

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.